Navigation Links
DrugRisk Update: Panel To Decide Fate of Januvia Lawsuits Next Week
Date:6/22/2013

New York, NY (PRWEB) June 22, 2013

The diabetes drug safety advocates at DrugRisk.com are announcing new information on the site for those patients taking the medications Januvia or Janumet. A federal panel will meet next week to decide which court venue will handle growing lawsuits alleging the drugs caused cancer*.

The goal of DrugRisk is to improve the safety of patients taking popular prescription drugs like Januvia and Janumet by providing the latest warnings, recalls, studies and legal news. Visitors can see if others are experiencing similar side effects and decide if they need legal advice.

Januvia and Janumet are pill-form diabetes medications prescribed to help those with type-2 diabetes control blood sugar. The drugs were two of the best-selling for Merck in recent years, with sales of over $4 billion last year**.

The resource center contains studies suggesting Januvia and Janumet may be linked to cancer. A 2011 study from UCLA indicated the drug could increase the risk of pancreatic cancer by 172% and thyroid cancer by 48%***. The FDA is also investigating the risk of Janumet and Januvia cancer after receiving reports that some patients who died showed signs of early pancreatic cancer cells****.

DrugRisk also added a report by Dr. Peter Butler, head of endocrinology at UCLA, warning that the Januvia pancreatic cancer risk was not detected in trials prior to FDA approval because the manufacturer used very young animals not as prone to pancreatic cancer*****.

Now, with 53 patients having already filed a Januvia lawsuit alleging cancer, the Judicial Panel on Multidistrict Litigation will meet on July 25th to determine where to consolidate the growing number of cases*. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, United States Judicial Panel on Multidistrict Litigation).

Anyone affected by cancer after taking Januvia or Janumet is encouraged to speak with a lawyer about their legal options. However, due to the specialized nature of federal drug injury cases, DrugRisk only recommends lawyers who have already handled Januvia lawsuits.

For more information on the research, side effects and litigation news related to Januvia and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*JPML, 6/12/13; jpml.uscourts.gov/sites/jpml/files/Hearing_Order-7-25-13.pdf
**Bloomberg, 2/25/13; bloomberg.com/news/2013-02-25/merck-bristol-diabetes-drugs-linked-to-pancreatitis-risk.html
***Gastroenterology, July 2011; ctsi.ucla.edu/education/files/publicview/training/docs/FDA-analysis.pdf
****FDA, 3/14/13; http://www.fda.gov/Drugs/DrugSafety/ucm343187.htm
*****New York Times, 5/31/13; nytimes.com/2013/05/31/business/a-doctor-raises-questions-about-a-diabetes-drug.html?hp&_r=1&

Read the full story at http://www.prweb.com/releases/januvia-lawsuit/pancreatic-thyroid-cancer/prweb10859222.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisk Center Announces Court Postponement of NuvaRing Lawsuits
2. DrugRisk Announces Alternative to Mirena IUD May Be Available Soon
3. DrugRisk Announces Updated Information on Mirena Lawsuits
4. DrugRisk Adds Latest Health Warnings and Lawsuit Updates for Yaz
5. DrugRisk Announces New Pradaxa Health Warning From Australia
6. DrugRisk Update: NuvaRing Lawsuit Trials to Begin This Year
7. DrugRisk Update: Court Allows Charges of Prior Fraud Into Pradaxa Lawsuit
8. DrugRisk Pradaxa Lawsuit Update: Court Denys Boehringer’s Protective Order Request
9. DrugRisk Pradaxa Update: Litigation Grows As New Study Adds to Risks
10. DrugRisk Update: Bayer Discloses $500 Million Remaining for Yaz Lawsuits
11. DrugRisk Update: Evidence Submitted in Actos Lawsuit Suggests Drug Maker Knew of Cancer Risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... Coco Libre, the maker of coconut water ... LA GRAMMY’s Style Lounge Event. Coco Libre will offer musicians and celebrities the company’s ... big event. The invitation-only gifting suite, held this year at the W Hollywood Hotel, ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman and ... J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns Director, VA ... Southern Nevada Healthcare System. This will be the first Fisher House in Nevada, ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... Pittsburgh metro area, celebrates the beginning of the latest charity campaign in their ... skills through art. Donations to this worthy cause are currently being accepted at: ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... Care.” , The print component of “Revolutionizing Cancer Care” is distributed ... York, Washington DC/Baltimore, and Seattle, with a circulation of approximately 250,000 copies and ...
(Date:2/12/2016)... Highlands Ranch, Colo. (PRWEB) , ... February 12, 2016 , ... ... particularly over the past 35 years. A president has access to health and wellness ... leader of the free world, no single individual has a schedule as frenetic as ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Feb. 12, 2016  Sequent Medical, Inc. announced today ... to evaluate the safety and effectiveness of the WEB™ ... ruptured intracranial aneurysms.  Prof Laurent Spelle , MD, ... Paris, France and Principal Investigator of ... France and Germany.  Although patients with ...
(Date:2/12/2016)... , Feb. 12, 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ... announced the Company will ring the Nasdaq Closing Bell ... New York at 4:00 p.m. ET on ... Aralez. Adrian Adams , will perform ... 3:50 to 4:00 p.m. ET.  A live webcast will ...
(Date:2/12/2016)... February 12, 2016 ... auf den ungedeckten medizinischen Bedarf bei Lungen- ... seines klinischen Forschungsprogramms bekannt. Das Programm, das ... Verbesserungen ihrer respiratorischen Funktionen und anderer klinischer ... ein Medizintechnikunternehmen, das sich auf den ungedeckten ...
Breaking Medicine Technology: